Bolt Biotherapeutics
BOLT
32 hedge funds and large institutions have $12.2M invested in Bolt Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 5 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.51% less ownership
Funds ownership: 2.97% → 2.45% (-0.51%)
11% less funds holding
Funds holding: 36 → 32 (-4)
28% less capital invested
Capital invested by funds: $17M → $12.2M (-$4.8M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$86.5K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$40.6K |
| 3 |
Mariner
Overland Park,
Kansas
|
+$27.9K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.8K |
| 5 |
Renaissance Technologies
New York
|
+$11.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.78M |
| 2 |
NM
Newtyn Management
New York
|
-$616K |
| 3 |
AI
Acuitas Investments
Seattle,
Washington
|
-$473K |
| 4 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$85.3K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$19.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Assenagon Asset Management
Senningerberg,
Luxembourg
| $13.5K | -$9.44K | -685 | -40% |
|
27
Osaic Holdings
Scottsdale,
Arizona
| $11.3K | +$1.63K | +118 | +16% |
|
28
Bank of America
Charlotte,
North Carolina
| $3.89K | +$3.71K | +269 | +868% |
|
29
JP Morgan Chase
New York
| $592 | +$55 | +4 | +10% |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $119 | – | – | – |
|
31
Barclays
London,
United Kingdom
| $90 | – | – | – |
|
|
SIC
32
Salem Investment Counselors
Winston Salem,
North Carolina
| $26 | – | – | – |
|
|
33
Citadel Advisors
Miami,
Florida
| – | -$1.78M | -118,376 | Closed |
|
|
AI
34
Acuitas Investments
Seattle,
Washington
| – | -$473K | -31,525 | Closed |
|
|
MAM
35
Marquette Asset Management
Minneapolis,
Minnesota
| – | -$85.3K | -5,690 | Closed |
|
|
SPIA
36
Steward Partners Investment Advisory
New York
| – | -$750 | -50 | Closed |
|
37
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$2 | – | – |
|
BOLT Hedge Fund Activity: Q3 2024 in Review
32 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q3 2024, worth a combined $12.2M — down 28% from $17M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BOLT and 1 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 9 added.
The largest buyer was Susquehanna International Group, adding an estimated $86.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.78M sold.
- 32 institutional investors held Bolt Biotherapeutics (BOLT) as of Q3 2024, down from 36 in Q2 2024.
- Funds reported $12.2M of Bolt Biotherapeutics stock for Q3 2024, down 28% quarter-over-quarter.
- 1 fund opened new Bolt Biotherapeutics positions in Q3 2024 and 5 closed out, a net change of -4 holders.
- The largest Bolt Biotherapeutics buyer in Q3 2024 was Susquehanna International Group, an estimated $86.5K added.
- The largest Bolt Biotherapeutics seller in Q3 2024 was Citadel Advisors, an estimated $1.78M sold.
Based on aggregated 13F filings for Q3 2024.